Johnson & Johnson
Johnson & Johnson is a global healthcare leader focused on the research, development, and manufacture of products dedicated to human health and well-being. The company operates as a holding company with a diverse portfolio spanning advanced pharmaceutical therapies and medical technologies. Its core value proposition lies in delivering innovative clinical solutions across a broad range of therapeutic areas and surgical specialties.
Financials
Based on Q3 2025 filing
Business Segments
Innovative Medicine
primaryFocuses on novel pharmaceutical therapies across immunology, oncology, neuroscience, infectious diseases, and cardiovascular metabolism. This segment drives growth through high-value prescription drugs and complex biologic treatments.
DARZALEX, STELARA, REMICADE, TREMFYA, IMBRUVICA, ERLEADA, XARELTO, SPRAVATO, CARVYKTI, INVEGA SUSTENNA, OPSUMIT, UPTRAVI
Wholesalers, Retailers, Hospitals, Healthcare professionals
MedTech
majorProvides a comprehensive portfolio of medical technology solutions for cardiovascular care, orthopaedics, general and advanced surgery, and vision care. The segment emphasizes interventional solutions and enabling technologies for professional clinical use.
Abiomed heart recovery technologies, Shockwave circulatory restoration products, ACUVUE contact lenses, TECNIS intraocular lenses, Mentor breast aesthetics, DePuy Synthes orthopaedic implants
Hospitals, Physicians, Nurses, Eye care professionals, Clinics
Segment Financials
REMICADE — Sales to customers (Note 9)
View metricInnovative Medicine — Research and development expense
View metricInnovative Medicine — Sales to customers (Note 9)
View metricMEDTECH — Research and development expense
View metricMEDTECH — Selling, marketing and administrative expenses
View metricMEDTECH — Total Assets
View metricBusiness Overview
Competitive Position
A leading global healthcare entity with significant market share in oncology and immunology, characterized by a massive R&D pipeline and a dominant position in the medical device market.
Geographies
United States, Europe, Asia-Pacific, Latin America
Customer Segments
Healthcare providers, Medical distributors, Government health programs
Upstream Dependencies
Raw material suppliers, Contract research organizations, Specialized chemical providers, Biotechnology patent licensors
Downstream Customers
Pharmacy benefit managers, Governmental payers (Medicare/Medicaid), Private insurance companies, Hospital procurement networks
Competitors & Partners
Competitors
Partners
Genmab A/S
GMAB
Owner of patent families related to DARZALEX licensed to J&J
AbbVie
ABBV
Collaboration partner for IMBRUVICA through its subsidiary Pharmacyclics
Bristol-Myers Squibb
BMY
Co-development or competitive peer in immunology and oncology
Medtronic
MDT
Major competitor and potential partner in medical technology standards
Johnson & Johnson FAQ
Common questions about Johnson & Johnson
Johnson & Johnson is a global healthcare leader focused on the research, development, and manufacture of products dedicated to human health and well-being. The company operates as a holding company with a diverse portfolio spanning advanced pharmaceutical therapies and medical technologies. Its core value proposition lies in delivering innovative clinical solutions across a broad range of therapeutic areas and surgical specialties.
Johnson & Johnson is scheduled to report earnings for Q1 2026 on April 14, 2026. Analysts estimate revenue of $23.5B.
Johnson & Johnson generated $92.1B in trailing twelve-month revenue with net income of $25.1B, representing a net margin of 27.3%. Gross margin stands at 68.1%, with free cash flow of $19.6B. These figures are based on the Q3 2025 filing.
Johnson & Johnson's key competitors include Pfizer, Merck & Co., Stryker, and others. These companies compete in similar markets and product categories.
Johnson & Johnson has approximately 134,400 employees.